nach oben

memo - Magazine of European Medical Oncology

Tipp

New developments in acute graft-versus-host disease

verfasst von: Hildegard T. Greinix, Margit Mitterbauer, MD, Werner Rabitsch, MD, Nina Worel, MD, Ulrike Just, MD, Robert Knobler, MD, Peter Kalhs, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a well-established curative treatment option for selected patients with hematologic and oncologic diseases. Acute graft-versus-host disease (GvHD) has remained a serious complication of HCT and is associated with high morbidity and mortality especially in patients not responding to first-line therapy with corticosteroids. So far, no standard for salvage therapy of acute corticosteroid-refractory GvHD has been established worldwide. Use of extracorporeal photopheresis results in high response rates, has a steroid-sparing effect and is associated with improved patients’ survival.

Vorheriger Artikel Endpoints in lung cancer trials: today’s challenges for clinical statistics

Nächster Artikel The role of maintenance strategies in lymphoma and CLL 

Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–61. PubMedCrossRef

Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78. PubMed

Paczesny S, Hanauer D, Sun Y, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45:1–11. PubMedCrossRef

Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56. PubMedCrossRef

Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institute of Health consensus criteria. Blood. 2011;117:3214–9. PubMedCrossRef

Jagasia M, Arora M, Flowers MED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307. PubMedCrossRef

Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant. 2011;17:167–75. PubMedCrossRef

Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health Consensus criteria. Biol Blood Marrow Transplant. 2007;13:1207–15. PubMedCrossRef

Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43:149–53. PubMedCrossRef

10.

Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409–17. PubMedCrossRef

11.

Kuzmina Z, Eder S, Böhm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56. PubMedCrossRef

12.

Greinix HT. Graft-versus-host disease. Uni-Med Science. 2008.

13.

Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304. PubMedCrossRef

14.

Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Brit J Haematol. 1997;97:855–64. CrossRef

15.

Martin PJ, Rizzo JD, Wingard JR, et al. First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63. PubMedCrossRef

16.

Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–93. PubMed

17.

Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94. PubMedCrossRef

18.

MacMillan M, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7. PubMedCrossRef

19.

Greinix HT, Knobler R. Extracorporeal photopheresis. De Gruyter. 2013.

20.

Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91:405–8. PubMed

21.

Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation. Br J Haematol. 2003;22:118–27. CrossRef

22.

Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265–73 PubMedCrossRef

23.

Greinix HT, Worel N, Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1747–8. PubMedCrossRef

24.

Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008;42:609–17. PubMedCrossRef

25.

Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant. 2008;42:421–5. PubMedCrossRef

26.

Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion. 2010;50:1359–69. PubMedCrossRef

27.

Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Brit J Haematol. 2012;158:30–45. CrossRef

28.

Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease—results from a survey among German-Austrian-Swiss HSCT centers. Biol Blood Marrow Transplant. 2013 Jan 29. doi:pil:S1083-8791(13)00054-2.

Titel: New developments in acute graft-versus-host disease
verfasst von: Hildegard T. Greinix
Margit Mitterbauer, MD
Werner Rabitsch, MD
Nina Worel, MD
Ulrike Just, MD
Robert Knobler, MD
Peter Kalhs, MD
Publikationsdatum: 01.06.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0080-1

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

New developments in acute graft-versus-host disease

Abstract

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

The role of maintenance therapy in metastatic colorectal cancer

Therapy with JAK 1/2 inhibitors for myelofibrosis

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network

Optimal surveillance strategy of localised testicular non-germ cell sex-cord stromal tumours

Isolated colonic metastasis from breast cancer 11 years after primary diagnosis

Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network 